

INFORMAZIONI PERSONALI



Concetta Micalizzi

📍 Genova, italia
📞 +39 0102477567 📞 +39 3402959728
✉️ concettamicalizzi@gaslini.org

Sesso F | Data di nascita 27/02/1955 | Nazionalità Italiana

ESPERIENZA PROFESSIONALE

- (1986 – a oggi) Dirigente medico
UOC Ematologia, IRCCS Istituto Giannina Gaslini, Genova, IT
▪ Incarico Alta Specialità Leucemie pediatriche al 2003 ad oggi
- (2015 – a oggi) Professore a contratto in Ematologia Pediatrica
Università di Genova
▪ Corso di laurea in Infermieristica Pediatrica

ISTRUZIONE E FORMAZIONE

- (1990 - 1991) Master of Science in Hematology,
Royal postgraduate medical school, University of London, Diploma ottenuto in Novembre1991.
- (1979 - 1983) Scuola di specialità in Pediatria
Università di Genova, diploma di Laurea ottenuto in luglio 1983 con voti 50/50 e lode
- (1973 - 1979) Facoltà di Medicina e Chirurgia
Università di Genova , diploma ottenuto in luglio 1979 con voti 110/110 e lode.
- (1973 - 1979) Facoltà di Medicina e Chirurgia
Università di Genova , diploma ottenuto in luglio 1979 con voti 110/110 e lode.
- (1968 - 1973) Liceo Classico
Liceo Classico Statale Cristoforo Colombo, Genova, Diploma maturità ottenuto in luglio 1973 con voti 57/60.

COMPETENZE PERSONALI

Lingua madre Italiano

Altre Lingue

Inglese

COMPRENSIONE

PARLATO

PRODUZIONE SCRITTA

Ascolto

Lettura

Interazione

Produzione orale

B2

C1

B1

B1

B2

Sostituire con il nome del certificato di lingua acquisito. Inserire il livello, se conosciuto

Livelli: A1/A2: Utente base - B1/B2: Utente intermedio - C1/C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

- Competenze comunicative • Presentazioni orali a numerosi congressi
- Competenze professionali • Maggiori campi di interesse Leucemie e HLH
 - Attualmente PI dei seguenti studi clinici :
 1. AIEOP-BFM LAL 2017, fase 3
 2. Novartis PKC421A2218 /midostaurin, fase 2
 3. Novartis CAMN107A2120, fase 3
 4. EsPhALL COGAALL 1631, fase 3
 5. JNJ-54767414 (daratumumab), fase 2
 6. IntReALL HR 2010, fase 3
 7. ACT15378- Isatuximab, fase 2
 8. ICC APL STUDY 02, fase 2
 9. Emapalumab (Anti-IFNγ) in HLH, fase
 10. Carfilzomib in ALL, fase 2
 - In precedenza coinvolta nei seguenti studi clinici
 - 1. BiTE: A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic (3 PATIENTS ENROLLED)
 - 2. CPKC412A2114 A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of twice daily oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory leukemia (4 PATIENTS ENROLLED)
 - 3. A phase 2, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety and activity of azacitidine and to compare azacitidine to historical controls in pediatric subjects with newly diagnosed advanced myelodysplastic syndrome or juvenile myelomonocytic leukemia before hematopoietic stem cell transplantation. (1 PATIENT ENROLLED)
- Altre competenze • Revisore scientifico per Frontiers in Pediatrics

ULTERIORI INFORMAZIONI

Pubblicazioni Autore/Co-autore di 99 pubblicazioni (OriginalArticles, Reviews, Editorials,) su riviste scientifiche internazionali

Le pubblicazioni seguenti descrivono I miei campi di interesse prevalenti degli ultimi 10 anni

1) Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.
Conter V, Aricò M, Basso G, Biondi A, Barisone E, Messina C, Parasole R, De Rossi G, Locatelli F, Pession A, Santoro N, **Micalizzi C**, Citterio M, Rizzari C, Silvestri D, Rondelli R, Lo Nigro L, Ziino O, Testi AM, Masera G, Valsecchi MG; Associazione Italiana di Ematologia ed Oncologia Pediatrica. Leukemia. 2010 Feb;24(2):255-64. doi: 10.1038/leu.2009.250. Epub 2009 Dec 17

2) HHV-8-related visceral Kaposi's sarcoma following allogeneic HSCT: report of a pediatric case and literature review.

Sala I, Faraci M, Magnano GM, Sementa A, di Marco E, Garaventa A, **Micalizzi C**,

Lanino E, Morreale G, Moroni C, Castagnola E. Pediatr Transplant. 2011 Feb;15(1):E8-11.

3)MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-Cell precursor acute lymphoblastic leukemia.

Tassano E, Acquila M, Tavella E, **Micalizzi C**, Panarello C, Morerio C. Genes Chromosomes Cancer. 2010 Aug;49(8):682-7. doi: 10.1002/gcc.20776

4)Refractory cytopenia of childhood with monosomy 7 presenting as isolated neutropenia in a patient with fragile site at 16q22.

Tassano E, Tavella E, **Micalizzi C**, Panarello C, Morerio C. Cancer Genet Cytogenet. 2010 Aug;201(1):70-1. doi: 10.1016/j.cancergen.2010.04.020.

5)Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.

Pillon M, Aricò M, Basso G, Locatelli F, Citterio M, **Micalizzi C**, Testi AM, Barisone E, Nardi M, Lombardi A, Rondelli R, Rosolen A; NHL-Committee of the Italian Association of Pediatric Hematology, Oncology. Pediatr Blood Cancer. 2011 Apr;56(4):544-50. doi: 10.1002/pbc.22787. Epub 2010 Dec 15.

6)Monosomal complex karyotype in pediatric mixed phenotype acute leukemia.

Tassano E, Tavella E, **Micalizzi C**, Scuderi F, Cuoco C, Morerio C. Cancer Genet. 2011 Sep;204(9):507-11. doi: 10.1016/j.cancergen.2011.08.015

7)Neuroradiologic findings and follow-up with magnetic resonance imaging of the genetic forms of haemophagocytic lymphohistiocytosis with CNS involvement.

Rego I, Severino M, **Micalizzi C**, Faraci M, Pende D, Dufour C, Aricò M, Rossi A. Pediatr Blood Cancer. 2012 May;58(5):810-4. doi: 10.1002/pbc.23405. Epub 2011 Nov 21

8)Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.

Miano M, Pistorio A, Putti MC, Dufour C, Messina C, Barisone E, Ziino O, Parasole R, Luciani M, Lo Nigro L, De Rossi G, Varotto S, Bertorello N, Petruzzello F, Calvillo M, **Micalizzi C**. Leuk Lymphoma. 2012 Sep;53(9):1693-8. doi: 10.3109/10428194.2012.663915. Epub 2012 Mar 13

9)New recurrent chromosome change in pediatric therapy-related myelodysplastic syndrome: unbalanced translocation 1/6 with cryptic duplication of short arm of chromosome 6.

Tassano E, Tavella E, Valli R, **Micalizzi C**, Cuoco C, Maserati E, Pasquali F, Morerio C. Leuk Lymphoma. 2012 Dec;53(12):2434-8. doi: 10.3109/10428194.2012.695778. Epub 2012 Jun 13

10) Early diverting colostomy for perianal sepsis in children with acute leukemia.

Pini Prato A, Castagnola E, **Micalizzi C**, Dufour C, Avanzini S, Pio L, Guida E, Mattioli G, Jasonni V, Disma N, Mameli L, Montobbio G, Buffa P. J Pediatr Surg. 2012 Oct;47(10):e23-7. doi: 10.1016/j.jpedsurg.2012.05.034.

11) Natural history of acute lymphoblastic leukemia in neurofibromatosis type 1 monozygotic twins.

Galbiati M, Lettieri A, **Micalizzi C**, Songia S, Morerio C, Biondi A, Dufour C, Cazzaniga G.

Leukemia. 2013 Aug;27(8):1778-81. doi: 10.1038/leu.2013.55. Epub 2013 Feb 21. No abstract available.

12) Developmental timing of mutations revealed by whole-genome sequencing of twins with acute lymphoblastic leukemia.

Ma Y, Dobbins SE, Sherborne AL, Chubb D, Galbiati M, Cazzaniga G, **Micalizzi C**, Tearle R, Lloyd AL, Hain R, Greaves M, Houlston RS.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7429-33. doi: 10.1073/pnas.1221099110. Epub 2013 Apr 8

13) Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia.

Lo Nigro L, Mirabile E, Tumino M, Caserta C, Cazzaniga G, Rizzari C, Silvestri D, Buldini B, Barisone E, Casale F, Luciani M, Locatelli F, Messina C, **Micalizzi C**, Pession A, Parasole R, Santoro N, Masera G, Basso G, Aricò M, Valsecchi M, Biondi A, Conter V; AIEOP—Scientific Committee of ALL.

Leukemia. 2013 Dec;27(12):2419-21. doi: 10.1038/leu.2013.149. Epub 2013 May 14.

14) Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia.

Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F, Luciani M, Lo Nigro L, Menna G, **Micalizzi C**, Santoro N, Testi AM, Zecca M, Biondi A, Pigazzi M, Rutella S, Rondelli R, Basso G, Locatelli F; AIEOP AML Study Group.

Blood. 2013 Jul 11;122(2):170-8. doi: 10.1182/blood-2013-03-491621. Epub 2013 May 14.

15) New targets in pediatric Acute Myeloid Leukemia.

Miano M, **Micalizzi C**, Calvillo M, Dufour C.

Immunol Lett. 2013 Sep-Oct;155(1-2):47-50. doi: 10.1016/j.imlet.2013.09.012. Epub 2013 Oct 8. Review.

16) Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations.

Manara E, Bisio V, Masetti R, Beqiri V, Rondelli R, Menna G, **Micalizzi C**, Santoro N, Locatelli F, Basso G, Pigazzi M.

Leukemia. 2014 May;28(5):1132-4. doi: 10.1038/leu.2013.339. Epub 2013 Nov 14

17) Validation of flow cytometric phospho-STAT5 as a diagnostic tool for juvenile myelomonocytic leukemia.

Hasegawa D, Bugarin C, Giordan M, Bresolin S, Longoni D, **Micalizzi C**, Ramenghi U, Bertaina A, Basso G, Locatelli F, Biondi A, Te Kronnie G, Gaipa G.

Blood Cancer J. 2013 Nov 15;3:e160. doi: 10.1038/bcj.2013.56

18) Intensive care unit admission in children with malignant or nonmalignant disease: incidence, outcome, and prognostic factors: a single-center experience.

Faraci M, Bagnasco F, Giardino S, Conte M, **Micalizzi C**, Castagnola E,

Lampugnani E, Moscatelli A, Franceschi A, Carcillo JA, Haupt R.
J Pediatr Hematol Oncol. 2014 Oct;36(7):e403-9.

19) Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study.

Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, Lo Nigro L, Santoro N, Aricò M, Ziino O, Pession A, Testi AM, **Micalizzi C**, Casale F, Zecca M, Casazza G, Tamaro P, La Barba G, Notarangelo LD, Silvestri D, Colombini A, Rizzari C, Biondi A, Masera G, Basso G.
Blood. 2014 Mar 6;123(10):1470-8. doi: 10.1182/blood-2013-10-532598. Epub 2014 Jan 10

20) Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.

Parasole R, Petruzzello F, Messina C, Barisone E, Pession A, Locatelli F, **Micalizzi C**, Cesaro S, Testi AM, De Matteo A, Varotto S, Berger M, Morello W, Menna G, Poggi V.
Leuk Lymphoma. 2015 Mar;56(3):650-5. doi: 10.3109/10428194.2014.927456. Epub 2014 Aug 4.

21) Targeting BAG-1: a novel strategy to increase drug efficacy in acute myeloid leukemia.

Aveic S, Viola G, Accordi B, **Micalizzi C**, Santoro N, Masetti R, Locatelli F, Basso G, Pigazzi M.
Exp Hematol. 2015 Mar;43(3):180-190.e6. doi: 10.1016/j.exphem.2014.10.016. Epub 2014 Nov 11.

22) Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.

Giona F, Putti MC, **Micalizzi C**, Menna G, Moleti ML, Santoro N, Iaria G, Ladogana S, Burnelli R, Consarino C, Varotto S, Tucci F, Messina C, Nanni M, Diverio D, Biondi A, Pession A, Locatelli F, Piocchetti A, Gottardi E, Saglio G, Foà R.
Br J Haematol. 2015 Aug;170(3):398-407. doi: 10.1111/bjh.13453. Epub 2015 Apr 20.

23) Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia.

Faraci M, Matthes-Martin S, Lanino E, Morreale G, Ferretti M, Giardino S, **Micalizzi C**, Baldazzi A.
Pediatr Transplant. 2016 Feb;20(1):158-61. doi: 10.1111/petr.12630. Epub 2015 Nov 14.

24) Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

Franca R, Rebora P, Bertorello N, Fagioli F, Conter V, Biondi A, Colombini A, **Micalizzi C**, Zecca M, Parasole R, Petruzzello F, Basso G, Putti MC, Locatelli F, d'Adamo P, Valsecchi MG, Decorti G, Rabusin M.
Pharmacogenomics J. 2017 Jan;17(1):4-10. doi: 10.1038/tpj.2015.83. Epub 2015 Dec

25) Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.

Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, Santoro N, Ziino O, Pession A, Testi AM, **Micalizzi C**, Casale F, Pierani P, Cesaro S, Cellini M, Silvestri D, Cazzaniga G, Biondi A, Basso G.

Lancet Haematol. 2016 Feb;3(2):e80-6. doi: 10.1016/S2352-3026(15)00254-9. Epub 2016 Jan 26.

26) CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.

Palmi C, Savino AM, Silvestri D, Bronzini I, Cario G, Paganin M, Buldini B, Galbiati M, Muckenthaler MU, Bugarin C, Della Mina P, Nagel S, Barisone E, Casale F, Locatelli F, Lo Nigro L, **Micalizzi C**, Parasole R, Pession A, Putti MC, Santoro N, Testi AM, Ziino O, Kulozik AE, Zimmermann M, Schrappe M, Villa A, Gaipa G, Basso G, Biondi A, Valsecchi MG, Stanulla M, Conter V, Te Kronnie G, Cazzaniga G.

Oncotarget. 2016 Sep 13;7(37):59260-59272. doi: 10.18632/oncotarget.10610.

27) Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome.

Minoia F, Bovis F, Davì S, Insalaco A, Lehmberg K, Shenoi S, Weitzman S, Espada G, Gao YJ, Anton J, Kitoh T, Kasapcopur O, Sanner H, Merino R, Astigarraga I, Alessio M, Jeng M, Chasnyk V, Nichols KE, Huasong Z, Li C, **Micalizzi C**, Ruperto N, Martini A, Cron RQ, Ravelli A, Horne A; Pediatric Rheumatology International Trials Organization, the Childhood Arthritis and Rheumatology Research Alliance, the Pediatric Rheumatology Collaborative Study Group, and the Histiocyte Society. J Pediatr. 2017 Oct;189:72-78.e3. doi: 10.1016/j.jpeds.2017.06.005. Epub 2017 Aug 12

28) Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.

Giona F, Saglio G, Santopietro M, Menna G, Putti MC, **Micalizzi C**, Iaria G, Santoro N, Ladogana S, Mura R, Burnelli R, Consarino C, Cosmi C, Moleti ML, Leszl A, Tucci F, Nanni M, Diverio D, Biondi A, Locatelli F, Foà R.

Br J Haematol. 2018 Mar;180(6):895-898. doi: 10.1111/bjh.14458. Epub 2016 Dec 16

29) Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.

Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, **Micalizzi C**, Putti MC, Rizzari C, Santoro N, Zecca M, Disarò S, Rondelli R, Merli P, Pigazzi M, Pession A, Locatelli F, Basso G.

Br J Haematol. 2017 Apr;177(1):116-126. doi: 10.1111/bjh.14523. Epub 2017 Feb 27.

30) Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients.

Bruno B, Busca A, Vallero S, Raviolo S, Mordini N, Nassi L, Cignetti A, Audisio E,

Festuccia M, Corsetti A, Depaoli L, Faraci M, **Micalizzi C**, Corcione S, Berger M, Saglio F, Caropreso P, Mengozzi G, Squadrone V, De Rosa FG, Giaccone L. Expert Rev Hematol. 2017 Jun;10(6):543-550. doi: 10.1080/17474086.2017.1326813. Epub 2017 May 24. Review

31) Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.

Locatelli F, Valsecchi MG, Möricke A, Zimmermann M, Gruhn B, Biondi A, Kulozik AE, Silvestri D, Bodmer N, Putti MC, Burdach S, **Micalizzi C**, Teigler-Schlegel A, Ritter J, Pession A, Cario G, Bielack S, Basso G, Klingebiel T, Vinti L, Rizzari C, Attarbaschi A, Santoro N, Parasole R, Mann G, Karawajew L, Haas OA, Conter V, Schrappe M. Blood. 2017 Nov 9;130(19):2146-2149. doi: 10.1182/blood-2017-05-782086. Epub 2017 Sep 22

32) Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia.

Strocchio L, Gurnari C, Santoro N, Putti MC, **Micalizzi C**, Zecca M, Cuccurullo R, Girardi K, Diverio D, Testi AM, Lo-Coco F, Locatelli F. Br J Haematol. 2018 Jul 20. doi: 10.1111/bjh.15507

33) Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience.

Giona F, Santopietro M, Menna G, Putti MC, **Micalizzi C**, Santoro N, Ziino O, Mura R, Ladogana S, Iaria G, Sau A, Burnelli R, Vacca N, Bernasconi S, Consarino C, Petruzzello F, Moleti ML, Biondi A, Locatelli F, Foà R. Acta Haematol. 2018 Sep 18;140(2):105-111. doi: 10.1159/000491546

34)Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP).

Parasole R, Valsecchi MG, Silvestri D, Locatelli F, Barisone E, Petruzzello F, Putti MC, **Micalizzi C**, Colombini A, Mura R, Mina T, Testi AM, Notarangelo LD, Santoro N, Casini T, Consarino C, Nigro LL, Ziino O, Giagnuolo G, Rizzari C, Conter V. Blood Cancer J. 2018 Nov 15;8(12):115.

35)Human Fibrinogen Concentrate and Fresh Frozen Plasma in the Management of Severe Acquired Hypofibrinogenemia in Children With Acute Lymphoblastic Leukemia: Results of a Retrospective Survey.

Giordano P, Grassi M, Saracco P, Luciani M, Colombini A, Testi AM, **Micalizzi C**, Petruzzello F, Putti MC, Casale F, Consarino C, Mura RM, Mastrodicasa E, Notarangelo LD, Onofrillo D, Pollio B, Rizzari C, Tafuri S, De Leonardis F, Corallo PC, Santoro N.J Pediatr Hematol Oncol. 2019 May;41(4):275-279.

36)Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.

Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, Ballerini A, Matteo C, Gerss J, Wuerthwein G, Silvestri D, Colombini A, Conter V, Biondi A, Schrappe M, Moericke A, Zimmermann M, von Stackelberg A, Linderkamp C, Fröhwald MC, Legien S, Attarbaschi

A, Reismüller B, Kasper D, Smisek P, Stary J, Vinti L, Barisone E, Parasole R, **Micalizzi C**, Zucchetti M, Boos J. Haematologica. 2019 Sep;104(9):1812-1821. doi: 10.3324/haematol.2018

37) Late mortality and causes of death among 5-year survivors of childhood cancer diagnosed in the period 1960-1999 and registered in the Italian Off-Therapy Registry.
Bagnasco F, Caruso S, Andreano A, Valsecchi MG, Jankovic M, Biondi A, Miligi L, Casella C, Terenziani M, Massimino M, Sacerdote C, Morsellino V, Erminio G, Garaventa A, Faraci M, **Micalizzi C**, Garrè ML, Pillon M, Basso G, Biasin E, Fagioli F, Rondelli R, Pession A, Locatelli F, Santoro N, Indolfi P, Palumbo G, Russo G, Verzegnassi F, Favre C, Zecca M, Mura R, D'Angelo P, Cano C, Byrne J, Haupt R; OTR-AIEOP Registry. Eur J Cancer. 2019 Mar;110:86-97.

38) Comment on: Invasive fungal infections in children with acute lymphoblastic leukemia.

Castagnola E, Palmisani E, Mesini A, Saffioti C, **Micalizzi C**, Dufour C. Pediatr Blood Cancer. 2020 Jan;67(1):e28035. doi: 10.1002/pbc.28035. Epub 2019 Oct 10

39) Bortezomib-Responsive Refractory Anti-N-Methyl-d-Aspartate Receptor Encephalitis.

Cordani R, **Micalizzi C**, Giacomini T, Gastaldi M, Franciotta D, Fioredda F, Buratti S, Morana G, Pirlo D, Renna S, Castagnola E, Risso M, Lanteri P, Vari MS, Mancardi MM. Pediatr Neurol. 2020 Feb;103:61-64. doi: 10.1016/j.pediatrneurol.2019.09.004. Epub 2019 Oct 19

40) Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.

Mussolin L, Lovisa F, Gallingani I, Cavallaro E, Carraro E, Damanti CC, Vinti L, Sala A, Micalizzi C, Santoro N, Piglione M, Cellini M, Buffardi S, Buldini B, D'Amore ESG, Biffi A, Pillon M. Br J Haematol. 2020 May;189(3):e108-e111. doi: 10.1111/bjh.16531. Epub 2020 Feb 20

41) Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, **Micalizzi C**, Mergen N, Mohammad A, Kormany WN, Eckert C, Möricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987.

42) Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report.

Mazzoni M, Dell'Orso G, Grossi A, Ceccherini I, Viola S, Terranova P, **Micalizzi C**, Guardo D, Massaccesi E, Palmisani E, Calvillo M, Fioredda F, Malattia C, Dufour C, Ravelli A, Miano M. J Pediatr Hematol Oncol. 2021 Feb 22.

43) Hemolysis and Neurologic Impairment in PAMI Syndrome: Novel Characteristics of an Elusive Disease.

Del Borrello G, Guardo D, **Micalizzi C**, Ceccherini I, Miano M, Gattorno M, Dufour C. Pediatrics. 2021 Mar

Appartenenza a associazioni

- Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP)
- Membro attivo del gruppo di Lavoro AIEOP ALL dal 1995 al 2019
- Membro attivo del gruppo di Lavoro AIEOP AMLdal 2000 al 2019
- Membro attivo del gruppo di Lavoro AIEOP MDS dal 1995 ad oggi
- Membro attivo del gruppo di Lavoro AIEOP HLH dal 1995 ad oggi
- Membro attivo del CD AIEOP dal 2012 al 2015

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

GENOVA 8 - 03 - 2021

